ANDA Renaissance: FDA Aims To Reduce Refuse-To-Receive Actions
This article was originally published in The Pink Sheet Daily
Executive Summary
About to start GDUFA negotiations, agency wants to enhance communication with sponsors to avoid returning their applications.
You may also be interested in...
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
Generic user fees could be segmented further by addition of new group.
Pink Sheet Podcast: Finally, A US FDA User Fee Deal, ‘Pandemic Is Over’ Take-Aways, Tpoxx Development Issues
Pink Sheet reporters and editor discuss the impact of the long wait for a user fee deal to be negotiated, how the FDA will interpret President Biden’s statement that the COVID-19 pandemic is over, and concerns with the clinical development of the monkeypox treatment Tpoxx.
Will US FDA User Fee Deal Allow BsUFA Reg Science Research To Start?
The FDA had picked grantees for the initial round of biosimilar regulatory science research, but told them not to start major activities until the user fee reauthorization was assured. Congress now appears to have reached deal for a ‘practically clean’ reauthorization.